Mebendazole compared with secnidazole-adult giardiasis-Phase III
Phase 3
- Conditions
- Giardiasis
- Registration Number
- RPCEC00000095
- Lead Sponsor
- Central Military Hospital Carlos J. Finlay
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Informed-consent form signed. Patients with 18 years and older.
Exclusion Criteria
Patients who had previously received any antiparasitic drug within 1 month before entering the study. Have known about any hypersensitivity to any of the drugs in use. Have any immunodeficiency disease. Have any hepatic disease. Have any renal disease. Have any cardiovascular disease. Have any haematological disease. Have used other drugs joined to the drugs in use. Women were pregnant or lactation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Parasitological answer (Cured: If no Giardia cysts or trophozoites be found in any of the three post-treatment faecal simples, Not cured: Other case (microscopical examination as direct wet mount and Ritchie concentration. Measuring time: 3, 5 and 7 days after treatment completion. Clinical answer (Without clinical manifestations, with a relieve of the clinical manifestations, with the same clinical manifestations). Measuring time: 12 days after treatment completion.
- Secondary Outcome Measures
Name Time Method Adverse Events (description of the events). Measuring time: 3 days after treatment completion. Intensity of AE (Slight, moderate or severe, taking into account the grade of disfunction produced by the event). Measuring time: 3 days after treatment completion.